K-ras gene mutation

11 clinical trials

Quick filters

Clinical trials for K-ras gene mutation

11 trials across Europe

See all trials →

Quick filters

11 Clinical trials

K-ras gene mutation+1

Recruiting

Registered drugNo placebo

A study of pembrolizumab, cetuximab, and MK-1084 for patients with advanced or metastatic non-small cell lung cancer with KRAS G12C mutations

Registered drugNo placebo

Finland

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

K-ras gene mutation+1

Recruiting

Registered drugNo placebo

Evaluation of Safety, Pharmacokinetics, and Efficacy of RO7782493 and Panitumumab in Advanced Solid Tumors with KRAS G12D Mutation

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Panitumumab
Sponsor:Genentech Inc.

Contact Research Centre

K-ras gene mutation+2

Recruiting

Registered drugNo placebo

Study of divarasib and pembrolizumab compared to standard chemotherapy in previously untreated KRAS G12C-mutated advanced non-small cell lung cancer

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Budesonide
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

K-ras gene mutation+1

Recruiting

Registered drugNo placebo

Study of MK-1084, cetuximab and mFOLFOX6 combination compared to mFOLFOX6 with or without bevacizumab for patients with KRAS G12C-mutant advanced colorectal cancer

Registered drugNo placebo

Finland

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

K-ras gene mutation+2

Not recruiting

Registered drugNo placebo

Study Comparing Divarasib, Sotorasib, and Adagrasib for Patients with Advanced or Metastatic KRAS G12C-Positive Non-Small Cell Lung Cancer

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

K-ras gene mutation+3

Not recruiting

InvestigationalNo placebo

Study of JDQ443, TNO155, and Tislelizumab for Patients with Advanced Solid Tumors with KRAS G12C Mutation

InvestigationalNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Batoprotafib
Sponsor:Novartis Pharma AG

Contact Research Centre

See all trials →

K-ras gene mutation

Clinical trials for K-ras gene mutation

K-ras gene mutation+1

A study of pembrolizumab, cetuximab, and MK-1084 for patients with advanced or metastatic non-small cell lung cancer with KRAS G12C mutations

K-ras gene mutation+1

Evaluation of Safety, Pharmacokinetics, and Efficacy of RO7782493 and Panitumumab in Advanced Solid Tumors with KRAS G12D Mutation

K-ras gene mutation+2

Study of divarasib and pembrolizumab compared to standard chemotherapy in previously untreated KRAS G12C-mutated advanced non-small cell lung cancer

K-ras gene mutation+1

Study of MK-1084, cetuximab and mFOLFOX6 combination compared to mFOLFOX6 with or without bevacizumab for patients with KRAS G12C-mutant advanced colorectal cancer

K-ras gene mutation+2

Study Comparing Divarasib, Sotorasib, and Adagrasib for Patients with Advanced or Metastatic KRAS G12C-Positive Non-Small Cell Lung Cancer

K-ras gene mutation+3

Study of JDQ443, TNO155, and Tislelizumab for Patients with Advanced Solid Tumors with KRAS G12C Mutation

Filter the trials

Prefer not to search? Our Concierge searches the trials for you.